KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Total Non-Current Liabilities: 2014-2025

Historic Total Non-Current Liabilities for Xenon Pharmaceuticals (XENE) over the last 1 years, with Sep 2025 value amounting to $45.2 million.

  • Xenon Pharmaceuticals' Total Non-Current Liabilities was N/A to $45.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.2 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2016, which is 26.38% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $45.2 million for Q3 2025, which was up 1,184.61% from $3.5 million recorded in Q4 2016.
  • In the past 5 years, Xenon Pharmaceuticals' Total Non-Current Liabilities ranged from a high of $45.2 million in Q3 2025 and a low of $45.2 million during Q3 2025.
  • Over the past 1 years, Xenon Pharmaceuticals' median Total Non-Current Liabilities value was $45.2 million (recorded in 2025), while the average stood at $45.2 million.